WISP1 (Wnt1 inducible signaling pathway protein 1, CCN4) is a member of the secreted extracellular matrix-associated proteins of the CCN family and target gene of the Winglesstype (WNT) signaling pathway. Growing evidence links the WNT signaling pathway to the regulation of adipogenesis and low-grade inflammation in obesity. Here we aim to validate WISP1 as a novel adipokine.
The obesity epidemic is a growing health, social and economic problem worldwide (1) .
Central obesity and metabolic syndrome are independent risk factors for type 2 diabetes, cancer, nonalcoholic fatty liver disease and insulin resistant state (1, 2) . Over the past decade, a unifying mechanism behind the pathogenesis of obesity-associated diseases has given birth to the concept of "metainflammation" which describes the chronic low-grade inflammatory response to obesity (3) . The limited expandability of adipose tissue is another determinant in the pathogenesis of obesity-associated diseases (4) . Furthermore, abundant evidence, mostly derived from mouse studies, links the Wingless-type (WNT) signaling pathway to the regulation of adipogenesis (5, 6) and inflammation (7) in obesity.
WNT-signaling family members are secreted glycoproteins that are acting in both autocrine and paracrine fashions to regulate cell proliferation, cell fate, differentiation and organism development (8, 9) . The WNT signaling network consists of multiple so-called "canonical" and "non-canonical" pathways which lead to tightly controlled cell remodeling.
WNT-inducible signaling pathway protein-1 (WISP1, also known as CCN4) belongs to the CCN family of extracellular matrix proteins and is a downstream target gene of the canonical WNT signaling pathway (10) . Experimental evidence suggests that the other CCN family members such as WISP2 and nephroblastoma overexpressed protein (NOV) participate in the pathogenesis of obesity and associated diseases (5, 6, 11, 12) , but no data are available on the possible relationship between WISP1 and obesity. Similar to the majority of CCN proteins, WISP1 consists of four globular modules which bear analogy to various extracellular protein domains. Module I is homologous to the insulin-like growth factor (IGF) binding domain.
Module II is a von Willebrand factor type C repeat module and module III represents thrombospondin type I which is important for cell attachment. Module IV consists of a Cterminal domain (13) . WISP1 is expressed in various organs and tissues including heart, pancreas, lung, kidney, small intestine, ovaries, spleen and brain and, in some of these tissues,
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Diabetes acts anti-apoptotic through PI3K and Akt pathways (14) . WISP1 possesses a regulatory function in skeletal growth and bone repair (15) . It regulates mesenchymal proliferation and osteoblastic differentiation as well as chondrogenic differentiation (16) . Moreover, WISP1 is upregulated in a variety of cancers (17) and has been associated with invasion of cholangiocarcinoma (18) . Thus, WISP1 can determine the onset and progression of apoptosis and autophagy during normal physiology, acute illness or chronic degenerative disorders (14) .
No data are currently available regarding effects of WISP1 on insulin target tissues, including liver and fat. In the present study, we combined in vitro experiments with four independent clinical studies, aiming to validate WISP1 as a novel adipokine, and to characterize the association of WISP1 with parameters of the metabolic syndrome. We show that 1) WISP1 is a novel adipokine released from differentiated human adipocytes; 2) WISP1 expression was substantially elevated in visceral fat tissue (VAT) rather than in subcutaneous fat tissue (SAT) in glucose tolerant subjects; 3) WISP1 expression correlated with insulin sensitivity, adiponectin and markers of adipose tissue inflammation; 4) weight reduction decreased WISP1 expression in SAT as well as circulating WISP1 levels in plasma; and 5)
hepatic WISP1 expression showed no association with ectopic fat accumulation in obesity.
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RESEARCH DESIGN AND METHODS
Cohort I
Paired samples of VAT and SAT were obtained from 75 Caucasian men (n=40) and women (n=35) who underwent abdominal surgery and were metabolically characterized as described (26). Percentage body fat was measured by dual-energy X-ray absorptiometry (DEXA). In the subgroup (n=52), abdominal visceral fat content was measured by MRI as described previously (27). Insulin sensitivity was assessed with the euglycemic-hyperinsulinemic clamp method as described previously (28). Macrophage content in VAT and SAT samples was visualized in adipose tissue sections (stained with hematoxylin and eosin) by additional staining against CD68 (1:200; DAKO) as described previously (26). A total of 100 cells were studied from each slide and CD68 positive cells were counted. Adipocyte cell size in VAT and SAT were analysed in adipose tissue sections as described previously (26).
Cohort II
Effects of weight reduction were studied in 49 subjects kept on an 8-week low-calorie diet Participants who achieved a weight loss of at least 8% after 8 weeks were selected for the study. A detailed description of the study design has been previously published (19).
Percentage of body fat was measured by dual-energy X-ray absorptiometry. Plasma samples and subcutaneous adipose tissue biopsies were collected after overnight fasting before and after weight loss.
Cohort III
In our human liver study, 47 patients met the inclusion criteria, gave informed consent and were enrolled as recently detailed (29). Comparable to liver tissue, perfused samples of VAT mmol/l (140 mg/dl) (n=8), as described previously (30). Venous blood samples for analysis of hormones were taken at -70, 0, +210, +230 and +240 min, timed from the start of insulin infusion, and subcutaneous adipose tissue biopsies were taken before and after infusions (t=-40 min and +240 min).
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In cohorts I and III, paired samples of visceral adipose tissue and subcutaneous adipose tissue were obtained from the same sites during abdominal surgery by knife extraction. In cohorts II and IV, subcutaneous adipose tissue biopsies were taken by needle aspiration from contralateral sites at the level of the umbilicus. All samples were immediately flash-frozen in liquid nitrogen and stored at -80 °C for mRNA extraction.
Study I was approved by the ethics committee of the University of Leipzig, Germany and studies II-IV were approved by the ethics committees of (1) Potsdam University, Potsdam, Germany, (2) State Medical Association of Brandenburg, Germany and (3) Charité University Medicine, Berlin, Germany. All subjects gave written informed consent before taking part in the study.
Biochemical measurements
Biochemical measurements were performed by routine methods. WISP1 in plasma and medium samples were detected by commercial assay (WISP1 ELISA, RayBiotech Inc, GA, USA). For this, medium samples were concentrated using Vivaspin 2 concentrators (Sartorius, Germany). Cytokine release in cell culture medium was quantified using ProcartaPlexTM Multiplex Immunoassays (eBioscience, Germany).
Animal study
Animal protocols were approved by the local governmental animal ethic review board (State of Brandenburg, Germany). Twelve-week-old male C57Bl/6J mice were kept on either a control diet (10 kcal-% fat, 20 kcal-% protein, 70 kcal-% carbohydrate, 3.85 kcal/g) or a high fat diet (60 kcal-% fat, 20 kcal-% protein, 20 kcal-% carbohydrate, 5.24 kcal/g) (Research Diets, Inc., USA) containing for 6 weeks. WISP1 mRNA expression was measured in epididymal white adipose tissue, liver and gastrocnemius muscle.
Page 9 of 39 Diabetes
Cell culture
Human monocyte-derived macrophages were differentiated from isolated blood monocytes in RPMI 1640 medium supplemented with 10% HyClone FCS (Thermo Scientific, USA) and 50 ng/ml of human granulocyte-macrophage colony-stimulating factor (Peprotech, Germany) for 7 days and stimulated with recombinant human WISP1 (E.Coli, Endotoxin < 0,1 ng/µg of protein; Peprotech, Germany) from 50 ng/ml to 1.5 µg/ml for 24h. Table 1 .
Western blotting
Semi-dry immunoblots were performed with antibodies specific to phospho-p44/42 MAPK Mann-Whitney-U test or Student's t-test was applied to estimate differences between groups.
P-value of < 0.05 was considered significant.
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RESULTS
WISP1 gene expression in subcutaneous and visceral adipose tissue is associated with markers of insulin sensitivity and adipose tissue inflammation
Baseline characteristics of the cohort's I-IV are summarised in Table 1 . WISP1-mRNA expression in VAT was higher than in SAT in normal glucose tolerant subjects in the cohort I ( In cell culture experiments, we found that WISP1 mRNA was expressed in human mesenchymal stem cell derived adipocytes, and its expression was further increased during adipocyte differentiation ( Figure 1 -H and Suppl. Fig. 1 
-A-B). The increase of WISP1 mRNA
Page 12 of 39 Diabetes expression during adipocyte differentiation was accompanied by an elevation of intracellular WISP1 protein expression (Suppl. Fig. 1-C) as well as of WISP1 release into the culture medium ( Fig.1-I ). WISP1 expression was found neither in human monocytes nor in human monocyte-derived M-and GM-macrophages (data not shown).
We next stimulated human macrophages and human mesenchymal stem cell-derived adipocytes with WISP1 for 24 hours. In the macrophage culture, we observed a significant and dose-dependent, WISP1-induced increase of IL6, TNFA, IL1B, and IL10 at mRNA expression level, as well as at protein level in the culture medium (Fig. 2, Fig. 3-A) .
Moreover, WISP1 induced an increase of the expression of inflammatory M1 markers of macrophage polarisation, CCR7 and COX2. In line with this, expression of M2 marker CD36 and in tendency also CD163 were decreased (Fig. 3-B) . By contrast, we did not observe a WISP1-mediated response in adipocytes with regard to TNFA, IL1B, and IL10, either at mRNA level or in the culture medium. It is of note that the IL6 concentration in the culture medium of adipocytes was decreased after stimulation with WISP1 ( Fig. 2-B) . We also found no influence of WISP1 on the adipocyte differentiation in vitro analyzed using the oil red staining (Suppl. Figure 1 -B) and mRNA expression of adipocyte markers (data not shown).
Moreover, we observed no effects of WISP1 on the activation of insulin signaling in adipocytes, as measured by quantification of phosphorylated Akt and ERK protein levels (Suppl. Fig. 2 ).
WISP1 is inversely regulated by high fat diet induced obesity and weight loss
We next examined the expression of WISP1 in the SAT of subjects who underwent weight loss using a low-caloric diet (19). We observed a reduction of WISP1 mRNA expression in SAT after the weight loss (p=0.04), whereas WISP1 level in plasma was not significantly changed in the general cohort (Fig. 4-A-B) . Nevertheless, basal WISP1 mRNA expression in Circulating WISP1 also demonstrated a tendency to decrease only in female subjects (27.5%, p=0.13). Female subjects had more body fat before diet intervention (p=0.023) and archived less reduction of body fat content than male subjects (p=0.001). Interestingly, women also showed higher WISP1 plasma level before weight loss (934±199 pg/ml vs. 2104±472 pg/ml, p=0.035, for male and female subjects, respectively). No significant differences of other metabolic parameters between males and females before weight loss or in weight loss-induced changes were found.
To test the hypothesis that WISP1 expression is increased in diet-induced obesity, we studied male mice, which were randomized into either a control diet or high fat diet (HFD). 
Hepatic WISP1 expression has no association with ectopic fat accumulation in obesity
To determine whether ectopic fat accumulation may influence tissue WISP1 expression in humans, we studied paired samples of liver, SAT and VAT tissue from non-NASH subjects and patients with nonalcoholic fatty liver disease (NAFLD), where the disease is strongly associated with visceral obesity. Liver samples and VAT both demonstrated higher WISP1
expression when compared with SAT, and no difference with VAT ( Figure 5-A) . Hepatic WISP1 mRNA was detectable in 65% of non-NASH and 46% of NASH subjects, with no 
WISP1 is up-regulated by insulin in human adipocytes in vitro but not by the acute insulin infusion in vivo
Gene expression of WISP1 was increased after stimulation with 100nM insulin for 4 hours (Figure 6-A) . To elucidate pathways involved in WISP1 regulation by insulin, 3T3-L1 adipocytes were pretreated with vehicle, PI3K inhibitor LY294002, MAPK inhibitor PD098059 or IGF-1R kinase inhibitor NVP-AEW541 30 min before insulin stimulation. All these inhibitors abolished the induction of WISP1 expression upon insulin treatment ( Figure   6 -B).
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In the steady-state of the hyperinsulinemic-hyperglycemic clamp experiments, circulating insulin levels increased to 754.4±321.7 pmol/l and were higher than in the hyperinsulinemic-euglycemic clamp (392.7±77.3 pmol/l; p<0.001). We observed no effect of insulin on WISP1 expression in SAT in the hyperinsulinemic-euglycemic or hyperinsulinemic-hyperglycemic clamp in overweight glucose-tolerant subjects in vivo ( Figure 6 C-D).
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DISCUSSION
Our results show that the CCN family member WISP1 is a novel adipokine which is released by fully differentiated human adipocytes and stimulated cytokine responses in macrophages.
WISP1 release increases substantially during fat cell differentiation. A comparison of mRNA expression in mature adipocytes with pre-adipocytes and monocyte-derived macrophages as well as the comparison of adipose and liver tissue showed that adipocytes are likely to be a major source of WISP1 released into the circulation.
WISP1 is involved in the regulation of apoptosis and autophagy in a broad spectrum of neuronal, musculoskeletal, immunologic and cancer diseases (14) . Recent studies show that other CCN family members are closely linked to adipogenesis (5, 6, 11), but no data exist about the role of WISP1/CCN4 in obesity and associated diseases. We found that WISP1 gene expression and WISP1 protein production is up-regulated during human adipocyte differentiation. Further, we conducted a systematic investigation of WISP1 gene expression in human paired SAT and VAT samples, in a cohort of healthy glucose-tolerant subjects with different degrees of body weight. In contrast to another CCN family member, WISP2 (12), WISP1 was highly expressed in VAT and moderately expressed in SAT. Interestingly, WISP1 expression correlated negatively with insulin sensitivity, circulating adiponectin levels and with visceral fat content as measured by MRI, suggesting that WISP1 may be a useful marker of visceral fat accumulation and insulin resistance. In support of this hypothesis, we observed only borderline association of WISP1 expression in SAT and VAT with BMI and waist-to-hip ratio. Moreover, we observed a positive correlation of WISP1 with macrophage infiltration in both SAT and VAT. Based on the possible contribution of macrophages to effects described in adipose tissue, we also examined WISP1 expression in cultures of primary human monocytes and macrophages and were unable to detect WISP1. We observed reduced WISP1 gene expression in SAT and decreased circulating WISP1 levels after weight reduction in female participants. Interestingly, female subjects had more body fat and higher WISP1 plasma level before weight loss in comparison with male subjects. While human white adipose tissue displays a high adipocyte turnover, the total number of adipocytes in adults remains constant even after weight reduction (21). Thus, it is likely that the observed down-regulation in SAT reflected decreased expression of WISP1 in adipocytes but not a decreased adipocyte number. Additionally, WISP1 expression in liver was moderate and was not up-regulated in the subjects with NAFLD in our study.
Furthermore, we observed no association between different biochemical and anthropometrical markers of obesity and hepatic gene expression of WISP, suggesting that WISP1 is not involved in hepatic fat accumulation. Thus, the weight loss-induced changes in circulating WISP1 originated most likely from adipose tissue rather than from the liver or other organs.
Interestingly, another CCN family member, NOV, is associated with obesity and NOV levels in circulation are decreased after weight reduction due to bariatric surgery (11) . In line with Page 18 of 39 Diabetes our data, circulating NOV levels are higher in women when compared with male subjects (11) . Thus, the gender differences in the changes of WISP1 concentration after weight loss in our study might reflect regulation of CCN peptides production by sexual hormones (22) and needs further investigation. The reduction in circulating CCN proteins after weight loss could reflect down-regulation of the WNT-signalling pathway in different tissues such as adipose tissue and muscle in these subjects. WISP1 increase has been found in a variety of cancers (17) and the novel variant of WISP1 is associated with invasion of cholangiocarcinomas (18) .
Central obesity and metabolic syndrome are independent risk factors for cancer (23). The effects of circulating WISP1 on tissue regeneration and proliferation are not studied in vivo, but given the proliferative properties of WISP1, it may be a marker of malignancy risk in obesity, which deserves further investigation.
Insulin is an important regulator of adipocyte differentiation and function (24) and the cross-talk between insulin and the WNT signalling pathway occurs at multiple levels in murine preadipocytes (25). Anti-apoptotic and proliferative effects of WISP1 are mediated via the PI3K/Akt pathway (14) , suggesting that WISP1 may affect insulin signaling. We did, however, not observe such impact of WISP1 in vitro, whereas we found that the other way around, insulin signalling increases WISP1 gene expression in human adipocytes. This finding could not be easily translated to the in vivo situation, since short exposition of patients/subjects to hyperinsulinemia during clamp experiments had no effect on WISP1 expression in SAT. Several causes may explain the observed discrepancy between in vitro and in vivo experiments: firstly, the systemic insulin concentration during clamp experiments does not reflect the local intra-tissue insulin concentration, which was possibly lower compared to the insulin concentration in cell experiments; secondly, insulin induces multiple metabolic changes in the body, which can influence WISP1 expression and/or production and minimize the direct effect of insulin on adipocytes. Moreover, the subjects investigated were moderately Page 19 of 39 Diabetes insulin-resistant and thus permanently exposed to elevated insulin levels during the clamps while cell cultures were insulin-deprived and then exposed to much higher doses of insulin.
Since the cell culture data prove the ability of insulin to augment WISP1 expression, in vivo effects are probably affected by chronic exposure, are slower and less dependent on dosage.
Taken together, our data shows that WISP1 is a novel adipokine that is substantially overexpressed in visceral fat from obese subjects and reflects insulin resistance and adipose tissue inflammation. Weight changes regulate circulating WISP1 levels and WISP1 expression in adipose tissue. Therefore, we propose that WISP1 is a novel link between obesity and inflammation. Representative western blots are shown. * p < 0.05, ** p < 0.01.
Supplemental Figure 2. WISP1 effects on the insulin signaling
Western blots (A) and densitometric analysis of total and phosphorylated Akt protein levels (B) or total and phosphorylated ERK (44 and 42 kDa) protein levels (C) in extracts from 3T3-L1 adipocytes treated with 100 nM insulin for 30 min with or without pretreatment with 500ng/ml recombinant WISP1 protein for 30 min (n = 3). * p < 0.05, ** p < 0.01. In the cohort I (n=75), WISP1 mRNA expression in VAT and SAT in the normal glucose tolerant subjects was measured (A) and correlations of WISP1 mRNA levels in VAT and SAT with fasting plasma insulin (B, C), macrophage infiltration in VAT and SAT (D, E), and insulin sensitivity (F, G) were analysed. In human mesenchymal stem cell derived adipocytes, WISP1 mRNA expression (H, n=10) and WISP1 protein release in the culture medium (I, n=3) were measured during cell differentiation. Medium samples were concentrated as described in Research Design and Methods * p<0.05, ** p<0.01, *** p<0.001. 
Supplemental Table 1. Primers used for real-time PCR
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